Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

  • Inventiva IVA and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.
  • Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the potential to receive up to $290 million in milestone payments. 
  • Related: FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients.
  • In its 1H earnings release, Inventiva said it targets the last patient's first visit for NATiV3 Phase 3 trial of lanifibranor in patients with NASH for H2 2023 vs. 1H 2023, with topline data from part 1 of the study now targeted for 2H of 2025.
  • The company says the delay is primarily due to a higher than initially projected screen failure rate resulting in a slower than anticipated enrollment rate hit by the Russia-Ukraine war and the pandemic.
  • With a cash balance of €76.4 million, Inventiva's Cash runway extended through Q4 2023, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility.
  • Price Action: IVA shares trading higher by 22.10% higher at $4.80 during premarket trading on Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!